Gastrointestinal stromal tumors (GIST) are rare and mesenchymal in origin with a yearly incidence of 10-15 cases per million people. If it is technically resectable, surgical resection is the mainstay of therapy regardless of tumor location,. Although complete (R0) resection can be achieved in up to 85% of patients with primary disease, approximately 50% of patients experience recurrence or metastases within 5 years of primary resection. Moreover, prior to 2000, the prognosis of patients with advanced, inoperable GIST was poor because the molecular mechanism had not sufficiently been elucidated, thus effective therapy was lacking. The tyrosine kinase inhibitor imatinib, which selectively inhibits tyrosine kinase KIT, has shown substantial clinical benefit for patients with GIST. In clinical trials, imatinib treatment resulted in response rates of 40%-55% and longer progression-free survival for patients with a KIT-positive unresectable or metastatic GIST. Furthermore, recent clinical trials have shown that giving imatinib after curative resection for high-risk cases prolonged recurrence-free survival and overall survival in an adjuvant setting.
In the present review, we update and discuss recent progress in the perioperative use of imatinib and other agents for localized GIST.
These new data improve our understanding of the multidisciplinary approach for treating advanced and localized GIST. This new information may lead to development of novel clinical targets and improve clinical management of GIST patients.
| GENERAL SURGICAL PRINCIPLES
For a resectable GIST (as confirmed by histological examination), surgical resection is the mainstay of therapy regardless of tumor location. The goal of surgery is to remove the tumor macroscopically with an intact pseudocapsule. Lymph node dissection is routinely unnecessary because lymph node metastases are extremely rare.
Organ-preserving and function-preserving surgery is oncologically allowed if negative resection margins can be achieved. Bischof et al demonstrated recently that a laparoscopic approach for gastric GIST was associated with low morbidity and a high rate of R0 resection, and the long-term oncological outcome was acceptable. Therefore, they recommended that a laparoscopic approach should be the preferred approach for gastric GIST in well-selected patients.
14 However, it remains unclear whether this procedure is applicable for larger GIST and for GIST at other sites because the tumor should be handled carefully to avoid rupture, which markedly increases the risk of disease recurrence. Therefore, laparoscopic resection for GIST should currently only be carried out by surgeons with expertise, and prospective studies are required to confirm the utility of the laparoscopic approach for GIST. Furthermore, even if complete resection is achieved for a larger tumor, the rate of recurrence increases with increasing size. 15 Therefore, adjuvant therapy with imatinib is recommended, as discussed below. For patients with a very large localized GIST, which is considered unresectable without risk of unacceptable morbidity or functional deficit (so-called marginally resectable GIST), preoperative imatinib may be recommended. Preoperative imatinib treatment is also an option to facilitate organ-and function-preserving surgery because esophagectomy for esophageal GIST, pancreatoduodenectomy for duodenal GIST, and abdominoperineal resection for rectal GIST may be invasive and impair quality of life.
Although the goals of neoadjuvant therapy involving imatinib are to preserve organ function, to avoid tumor rupture and to reduce the risk of complication, evidence of safety and efficacy for preoperative imatinib treatment remains to be established.
| NEOADJUVANT THERAPY
The high response rate of advanced GIST to imatinib has made it possible to adapt imatinib to the neoadjuvant setting. It is expected that neoadjuvant therapy can achieve organ-or function-preserving surgery, avoid tumor rupture, and reduce postoperative complications. Furthermore, the shrinkage of tumors treated with imatinib permits conservative and less invasive R0 resection, especially for GIST located at the esophagogastric junction, and in the duodenum and rectum. However, as there are few clinical trials of neoadjuvant therapy for GIST, evidence of the efficacy of neoadjuvant therapy remains to be established ( Recently, a phase II study for a neoadjuvant setting for large gastric GIST was reported from Asia. 18 Patients with a large gastric GIST (≥10 cm) received imatinib (400 mg/day) for 6-9 months before surgery. Forty-six of 53 patients enrolled in this study completed at least 6 months of dosage. The response rate was 62%, and R0 resection was carried out in 91% of patients. The 2-year OS was 89%.
These findings suggest that neoadjuvant imatinib therapy can be beneficial for larger gastric GIST. GIST. We will discuss the neoadjuvant setting below.
| Retrospective study
Several retrospective studies of neoadjuvant therapy have been reported. 19, 20 However, few data are available for primary GIST in the neoadjuvant setting, because most of these studies included both primary and recurrent or metastatic resectable GIST. Recently, in a larger retrospective study, 161 patients with locally advanced GIST who received preoperative imatinib (400 mg daily) was reported. 19 The primary tumor was located in the stomach (55%), rectum (20%), small intestine (11%), duodenum (10%), or esophagus (3%). Median duration of preoperative imatinib was 40 weeks.
Although the rate of R0 resection was 83%, two cases had disease progression before surgery. Five-year disease-specific survival and disease-free survival rates were 95% and 65%, respectively. Only 56% of patients received imatinib after surgery for at least 1 year.
The findings of this study suggested that neoadjuvant imatinib therapy was feasible and effective for locally advanced GIST. It is possible that the benefit from neoadjuvant therapy depends on tumor location. Neoadjuvant therapy can be beneficial for GIST located at the esophagogastric junction, duodenal, and rectum because complete resection for these tumors requires extensive organ disruption through esophagectomy, pancreatoduodenectomy, or abdominal perineal resection. For rectal GIST, in particular, several studies indicated the efficacy of neoadjuvant imatinib therapy. Jakob et al
showed that the rate of the negative surgical margin in patients after neoadjuvant therapy was significantly higher than that in patients without neoadjuvant therapy. 21 Also, all patients with a positive surgical margin who experienced recurrence after surgery did not receive imatinib before surgery. Tielen et al also showed that complete resection was achieved in 77% of patients given preoperative imatinib for rectal GIST. 22 Furthermore, sphincter-preserving surgery is achieved more often in patients who received imatinib, also leading to a reduction of local recurrence. Although Wilkinson et al also showed that neoadjuvant imatinib therapy can decrease both tumor size and mitotic activity, 23 suggesting that neoadjuvant therapy is a promising strategy for locally advanced GIST, a larger prospective study is required to resolve the clinical questions.
| Agents as neoadjuvant therapy
Only imatinib has been evaluated in previous studies. It remains unclear whether other agents including sunitinib and regorafenib are effective in the neoadjuvant setting as well as the adjuvant setting, although there is one case report using sunitinib as an active neoadjuvant therapy as a result of severe adverse events from imatinib. 24 Regarding the dose of imatinib, in the RTOG0132A/ACRIN6665 trial, 600 mg was given daily. 16 Most retrospective studies of neoadjuvant therapy used a dose of 400 mg daily. However, in the European Society For Medical Oncology (ESMO) guidelines, 800 mg imatinib daily is recommended for KIT exon 9 mutation cases, based on the finding that cases with KIT exon 9 mutation have an inferior response to imatinib in metastatic disease. 25 Therefore, it is necessary to evaluate the optimal dose of imatinib as neoadjuvant therapy in the context of the safety of subsequent surgery.
The optimal duration of imatinib treatment also remains unclear.
The best timing of surgery is the point of best response by the agent before secondary resistance to the agent is acquired. Median time of response to imatinib is 3 months, as reported in a phase II trial of imatinib for unresectable GIST, and the rate of response reached a plateau at 6 months. 26 Given these data, the optimal duration of neoadjuvant imatinib therapy appears to be 3-6 months.
| Evaluation of response
It remains controversial as to which is the best modality to evaluate the response of GIST to tyrosine kinase inhibitors (TKI). Contrast- 
| Postoperative management
There is no consensus on postoperative management for patients receiving neoadjuvant therapy. High-risk GIST patients are recommended to receive adjuvant imatinib therapy, as described above.
However, it may be desirable that patients with neoadjuvant therapy receive adjuvant imatinib therapy for several years, because the behavior of the original tumor before treatment may require adjuvant therapy. Notably, most patients in the RTOG0132 trial experienced recurrence within 2 years after discontinuation of imatinib. 16 Therefore, further study is needed to determine the risk factor for recurrence after neoadjuvant therapy.
| Clinical concerns for neoadjuvant therapy
Although neoadjuvant therapy appears beneficial for locally advanced GIST, several clinical problems need to be resolved as follows. First, histological confirmation of a GIST is necessary prior to neoadjuvant therapy according to the National Comprehensive Cancer Network (NCCN) and ESMO guidelines. 7, 8 Furthermore, testing for mutation in c-kit and platelet-derived growth factor receptor alpha (PDGFRA) mutational analysis is strongly recommended before neoadjuvant therapy to ensure the tumor has a genotype that is likely to respond to treatment. 7 hemorrhage. In these circumstances, it is possible that surgery will be required when the patient is in poor condition. It is critical to establish a system to promptly deal with an emergency situation.
| ADJUVANT THERAPY
The standard treatment for a primary resectable GIST without distant metastasis is surgery, with the aim of macroscopically complete resection with a negative margin. However, most high-risk patients experience recurrence within the first 5 years, despite complete curative surgery. 29 Therefore, adjuvant therapy is necessary to improve the prognosis for these patients. The success of imatinib in an advanced disease setting means that it is possible for high-risk patients to adapt to adjuvant therapy after curative surgery. NCCN and ESMO guidelines strongly recommend adjuvant therapy with imatinib for 3 years for patients with a significant risk of relapse. 7, 8 Several clinical trials have indicated the benefit of imatinib in an adjuvant setting, as shown in Table 2 .
| ACOSOG Z9000 (phase II)
The ACOSOG Z9000 trial was the first trial to evaluate the efficacy of imatinib as adjuvant therapy. 30 One hundred seven patients with complete resection of GIST >10 cm in size, tumor rupture, hemorrhage, or multifocal GIST received 400 mg imatinib daily for 1 year. Primary GIST, gastrointestinal stromal tumor; OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival.
endpoints, namely the rates of 1-, 2-, and 3-year recurrence-free survival (RFS), were 96, 60, and 40%, respectively. In an analysis according to specific mutations, the median RFS of patients with KIT exon 9 mutation and exon 11 mutation were 19 months and 42 months, respectively. In a multivariate analysis for prognosis, KIT exon 9 mutation and high mitotic rate were significantly associated with poorer prognosis.
This latter finding is consistent with a previous report that some mutations, including KIT exon 9, were associated with a poorer response to imatinib in the setting of advanced or metastatic disease.
| ACOSOG Z9001 (phase III)
In this trial, 713 patients who underwent a complete resection for KIT-positive primary GIST ≥3 cm were randomly assigned to a 1- 
| SSGXVIII/AIO (phase III)
The Scandinavian Sarcoma Group (SSG) XVIII trial was a large randomized controlled trial comparing 1 vs 3 years of adjuvant imatinib (400 mg daily) in high-risk resected GIST patients. 31 In this trial, high risk was defined as having at least one of the following: tumor size >10 cm, mitotic count >10/50 high-power field (HPF), tumor size Optimal duration At least 3-6 months prior to surgery may be required, but before secondary resistance (within 2 y).
Evaluation of response PET may give indication of imatinib activity after 2-4 weeks of therapy for early evaluation of response.
Postoperative management There is no consensus on adjuvant therapy for patients receiving neoadjuvant therapy. It may be desirable because the behavior of the original tumor before treatment may require adjuvant therapy.
Adjuvant therapy
Optimal imatinib dose Only the 400 mg daily dose was given in all previous phase III trials.
Optimal duration At least 3 y of imatinib treatment is recommended for high-risk GIST patients, but phase II trial of 5-year dose of adjuvant imatinib was reported.
Patient selection High-risk patients based on tumor size, mitotic rate, tumor location, and tumor rupture, mutation subtypes should also be considered during patient selection (PDGFRA exon 18 D842V mutation).
GIST, gastrointestinal stromal tumor; PDGFRA, platelet-derived growth factor receptor alpha; PET, positron emission tomography.
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| CONCLUSION
We review and summarize the clinical relevance and issues of neoadjuvant and adjuvant therapy for localized GIST (Table 3) . Although imatinib as neoadjuvant and adjuvant therapy clearly contributes to improving the prognosis for high-risk GIST, the optimal dose, duration, and patient selection for clinical settings remain controversial. Furthermore, molecular biological research including detailed mutational analysis will help guide personalized therapy for advanced GIST.
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